Publication:
The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia.

cris.virtual.author-orcid0000-0002-1300-7135
cris.virtualsource.author-orcid390b6c9e-e527-4470-91eb-cf13aadf0e3c
cris.virtualsource.author-orcidcb4ae777-24ff-48c5-a56c-248e1791bce6
cris.virtualsource.author-orcid1dc13a26-d1e9-4e4e-ae42-5894226d5825
cris.virtualsource.author-orcidb527b4ed-fa3f-49c3-a6ea-bb4d7eba37ae
cris.virtualsource.author-orcid38f6169a-2e5b-493f-ba97-b28636919736
cris.virtualsource.author-orcid523949fc-92c6-4c9e-8e44-58322d20a3c8
cris.virtualsource.author-orcid2ad04056-463d-4e6f-8b69-b3f214a76019
cris.virtualsource.author-orcid63da2016-37fe-4e5c-a599-ea7541e54c7f
datacite.rightsopen.access
dc.contributor.authorDraxler, Dominik Ferdinand
dc.contributor.authorBrodard, Justine
dc.contributor.authorZante, Björn
dc.contributor.authorJakob, Stephan
dc.contributor.authorWiegand, Jan Alexander Andreas
dc.contributor.authorKremer Hovinga Strebel, Johanna Anna
dc.contributor.authorAngelillo, Anne
dc.contributor.authorRovó, Alicia
dc.date.accessioned2024-10-11T17:18:19Z
dc.date.available2024-10-11T17:18:19Z
dc.date.issued2022-09-26
dc.description.abstractIn Covid-19, anticoagulation with heparin is often administered to prevent or treat thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment, caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Diagnosis of HIT is based on the combination of clinical parameters, allowing to determine the pretest probability, and laboratory testing for anti-PF4/heparin antibodies and confirmatory functional assays, such as the heparin-induced platelet activation (HIPA) test.We report the case of a patient with severe Covid-19 pneumonia requiring ECMO treatment, who developed recurrent clotting of the ECMO filter and a drop in platelet count under heparin treatment. He was therefore suspected to have HIT and the anticoagulation was switched to argatroban. Despite high clinical probability and high titres of anti-PF4/heparin antibodies, the functional HIPA test was negative. Nevertheless, argatroban was continued rather than to reinstate anticoagulation with heparin. Reevaluation 7 days later then demonstrated a strongly positive functional HIPA test and confirmed the diagnosis of HIT. Under anticoagulation with argatroban the patient gradually improved and was finally weaned off the ECMO.In conclusion, this case highlights the critical importance of clinical judgement, exploiting the 4 T score, given that Covid-19 patients may present a different pattern of routine laboratory test results in HIT diagnostics. The possibility of a false negative HIPA test has to be considered, particularly in early phases of presentation. In cases of a discrepancy with high clinical probability of HIT and/or high titre anti-PF4/heparin antibodies despite a negative HIPA test, a reevaluation within 3 to 5 days after the initial test should be considered in order to avoid precipitant reestablishment of unfractionated heparin, with potentially fatal consequences.
dc.description.sponsorshipUniversitätsklinik für Hämatologie und Hämatologisches Zentrallabor
dc.description.sponsorshipUniversitätsklinik für Intensivmedizin
dc.description.sponsorshipUniversitätsklinik für Kardiologie
dc.identifier.doi10.48350/173354
dc.identifier.pmid36163073
dc.identifier.publisherDOI10.1186/s12959-022-00411-0
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/87774
dc.language.isoen
dc.publisherBioMed Central
dc.relation.ispartofThrombosis journal
dc.relation.issn1477-9560
dc.relation.organizationDCD5A442BADDE17DE0405C82790C4DE2
dc.relation.organizationDCD5A442BB15E17DE0405C82790C4DE2
dc.relation.organizationDCD5A442C055E17DE0405C82790C4DE2
dc.relation.organizationFE9070E90049439CAFD7E6B2FE6653E3
dc.subjectCovid-19 Heparin-induced platelet activation test Heparin-induced thrombocytopenia
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleThe potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.issue1
oaire.citation.startPage55
oaire.citation.volume20
oairecerif.author.affiliationUniversitätsklinik für Kardiologie
oairecerif.author.affiliationUniversitätsklinik für Hämatologie und Hämatologisches Zentrallabor
oairecerif.author.affiliationUniversitätsklinik für Intensivmedizin
oairecerif.author.affiliationUniversitätsklinik für Intensivmedizin
oairecerif.author.affiliationUniversitätsklinik für Intensivmedizin
oairecerif.author.affiliationUniversitätsklinik für Hämatologie und Hämatologisches Zentrallabor
oairecerif.author.affiliationUniversitätsklinik für Hämatologie und Hämatologisches Zentrallabor
oairecerif.author.affiliationUniversitätsklinik für Hämatologie und Hämatologisches Zentrallabor
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2022-09-29 07:17:12
unibe.description.ispublishedpub
unibe.eprints.legacyId173354
unibe.journal.abbrevTitleThromb J
unibe.refereedtrue
unibe.subtype.articlecontribution

Files

Original bundle
Now showing 1 - 1 of 1
Name:
s12959-022-00411-0.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections